An increasing body of evidence suggests that solid tumours do not require the generation of new blood vessels, i.e. angiogenesis, to successfully grow, and to colonize normal tissue. Instead, many tumour cells make the best use of what they find: pre-existing blood vessels of the host. In these cases, the host vasculature is incorporated by the growing tumour, resulting in a new organ consisting of malignant and non-malignant cell types. In consequence, pre-existing vessels are exploited by the tumour for optimal access to oxygen and nutrients. In this perspective article, the argument is made that tumour cells might gain even more: that is, access to the very special microenvironment of the perivascular niche. Here, specific cues for invasion, metastasis, survival, stem-like features, dormancy and, potentially, also immune escape exist -for non-malignant and malignant cells alike. The consequence of the hijacking of normal blood vessels and their perivascular niches by tumours is that antiangiogenic agents have little chance to work, and that tumour cells are better protected from the adverse effects of cytotoxic and targeted therapies. Thus, disturbing vascular hijacking could make tumours less resistant to established therapies. Concepts of how to do this are just starting to be explored.
Introduction: tumours as organs
It is widely accepted that a tumour is not only a group of mutated cancer cells, but a newly formed organ in which various non-malignant cells and structures act as crucial conspirators during tumour progression and therapy resistance [1, 2] . In tumours, as is typical for organs, many cell types and extracellular structures have to dynamically interact in space and time to create something that has full functionality. Recent findings have added to this notion, demonstrating that single cancer cells within one tumour communicate and cooperate with each other in a complex but ordered manner that is, by itself, reminiscent of a functional organ [3] . As a consequence, the drawing of meaningful conclusions about central points of tumour biology requires deep insights into the pathoanatomy of the disease: no organ can be understood if its architecture is not. Complementing the advanced molecular techniques that dominate cancer research today, thorough classic histology, but also more advanced three-dimensional (3D) tissue analysis (e.g. confocal microscopy and 3D electron microscopy [4] ), and finally intravital microscopy, adding time as a crucial fourth dimension [5] [6] [7] , are essential to understand how the tumour organ works, how it can be best targeted, and how it might resist therapies.
A prime example of the potency of careful morphological analysis is the discovery of how the developing tumour organ can use pre-existing vascular environments of the host to thrive. This incorporation of an anatomical, physiological and molecular structure as complex as the normal blood vasculature is a remarkable ability of certain tumours. It has become clear that tumour cells can hijack molecular programmes involved in normal tissue development [2] . Apparently, they can also hijack developed tissue structures, which further blurs the line between normal and malignant. likely. In a recent study by Bridgeman et al, lung metastases of other cancer types were analysed, and showed even higher rates of a similar, non-angiogenic growth pattern, whereby pre-existing blood vessel are co-opted by cancer cells [11] . Some form of vascular co-option occurred in 80% of the lung metastases examined, with the highest numbers being seen for breast and colorectal cancer lung metastases, and the lowest for renal cancer lung metastases. These data are supported by careful histological examination of the early steps of lung metastasis formation in a mouse model, in which all six cell lines examined showed a distinct vascular co-option pattern after extravasation, most of them gradually stripping normal pneumocytes from the vessels, and replacing them over time [12] . Importantly, again in a mouse model, Bridgeman et al were able to link resistance to antiangiogenic treatment to the co-optive growth pattern: sunitinib had negligible effects on the lung metastasis burden, but had relevant effects on the primary tumour volume when the same cell lines were implanted subcutaneously, after which they grew in an angiogenic fashion [11] .
The liver is another organ with a distinct morphology of normal blood vessels embedded in more complex tissue structures, allowing detection of their eventual preservation in progressing tumours. Here, cancer cells of liver metastases can infiltrate the hepatic plates of the liver parenchyma and co-opt pre-existing sinusoidal vessels, rather than promoting angiogenesis [13] [14] [15] . Interestingly, it was recently demonstrated that the co-optive growth pattern was associated with poor response to the vascular endothelial growth factor A (VEGF-A) inhibitor bevacizumab, and occurred more frequently after bevacizumab treatment in patients [15] , which supports the notion that growth via co-option of pre-existing host vessels can be a mechanism of primary and adaptive resistance against antiangiogenic therapy. Likewise, in primary liver tumours (hepatocellular carcinomas), a recent animal study demonstrated a switch to a very similar co-optive growth pattern as a mechanism of secondary resistance after sorafenib treatment [16] . Finally, examination of a lung cancer metastatic lesion in the eye showed an atypical, but striking, growth pattern with prominent vascular co-option after bevacizumab treatment [17] . It must be emphasized, however, that the existing data obtained with different tumour entities do not provide a clear picture of whether the co-optive progression pattern after or during antiangiogenic therapies is merely a 'fall-back option' for tumours that are prevented from growing quickly by sprouting angiogenesis or other vascularization mechanisms [18] , or whether the antiangiogenic treatment creates a new situation in which a worse tumour progression pattern than before is induced.
As well as the lung, liver, lymph nodes [19] , adipose tissue [20] , and skin after ultraviolet irradiation [21] , the brain is now another organ for which we have indications for successful tumour progression by co-option of pre-existing blood vessels. This has been demonstrated both for primary brain tumours (gliomas) [22, 23] and for brain metastases [24] [25] [26] [27] [28] . Extensive vascular co-option is a particular hallmark of early brain metastasis formation in mouse models of melanoma, breast cancer and, sometimes, lung cancer, and appears to be an essential step in the brain metastatic cascade [24, 25] . Again, an association of this non-angiogenic, co-optive growth pattern with primary [24] and adaptive [29, 30] resistance to anti-VEGF-A therapy in gliomas and brain metastases has been reported.
Taken together, there is an overwhelming body of evidence today that many primary and metastatic tumour types in many organs do not exclusively depend on the formation of new blood vessels, but can use pre-existing ones of the host to thrive. This could provide one explanation for the often disappointing performance of antiangiogenic drugs in clinical trials [31] , but also points towards a potential solution: if vascular co-option can be inhibited along with angiogenesis, anti-tumour effects should be much greater. Unfortunately, the molecular mechanisms of vascular co-option are much less well understood than those of sprouting angiogenesis, and are just beginning to be explored [32] . In one recent study, the actin-related protein 2/3 complex was associated with vessel co-option in liver metastases [15] , suggesting that, not unexpectedly, basic mechanisms of cell motility play a role; however, these might be difficult therapeutic targets. In brain metastasis, the vascular basement membrane (BM) might provide a familiar soil within the microenvironment of the brain which is alien for carcinoma and melanoma cells, with tumour cell β1 integrin as one factor of crucial BM interaction [28] . It is of note that the luminal and abluminal parts of the vascular BM are produced by different cell types, and appear to be related to different functions, as demonstrated for various laminin isoforms in the brain [33] [34] [35] . These differences might also explain the preference of certain extracerebral tumour types for the endothelial versus abluminal site during host tissue invasion [36] . Other studies have suggested that bradykinin [37] , angiopoietin-2 [38] and the axon pathfinding molecule L1CAM [25] are involved in vascular co-option in primary and metastatic brain tumours. It is unclear, however, whether the latter mechanisms play a role outside the brain. It is more likely that organ-specific mechanisms exist, at least to some extent, increasing the complexity of developing inhibitory therapeutic strategies against vascular co-option by tumours.
How tumours hijack pre-existing vascular environments to thrive 269 tumour has grown to a certain size [39] . However, it is highly likely that there are more reasons for tumour cells to be attracted to (pre-existing) blood vessels. Using long-term intravital microscopy, we have demonstrated that, during brain metastasis, extravasated cancer cells need to maintain direct contact with the blood vessel wall to survive and thrive. Whenever this contact is lost, either initially or later during proliferation to brain micrometastases, the death of lung cancer, melanoma [24] and also breast cancer cells (unpublished observation) is inevitable. It is unlikely that access to oxygen and nutrients is the driving factor for vascular co-option in the brain, as high levels of vascularization and availability of glucose, owing to extensive neuronal metabolic demand, should grant sufficient access independently from blood vessel proximity. A similar phenomenon appears to apply to the early steps of the lung metastatic cascade [12] , making it likely that the perivascular niche is a crucial factor for metastatic colonization that is not limited to the brain.
There are many reasons why tumour cells can benefit from colonizing the perivascular niche. Higher local concentrations of angiocrine factors acting as (tumour) stem cell and progenitor cell active trophogens, such as bone morphogenetic protein (BMP) 2, BMP4, fibroblast growth factor 2, brain-derived neurotrophic factor, pigment epithelium-derived factor, placental growth factor, platelet-derived growth factor-β, VEGF-A, Ang-2, Jagged, and nitric oxide (NO), and various cytokines and chemokines, produced by the endothelial and other vascular wall cells and acting on tumour cells in a paracrine manner, constitute a plausible mechanism [40] .
Stemness is indeed an important aspect of the perivascular niche [41, 42] . In the bone marrow, intravital imaging technologies have contributed to the discovery of a perivascular niche that is crucial for long-term persistence of haematopoietic stem cells [43] [44] [45] , and also for providing essential cues in haematological malignancies [46] . In squamous skin tumours, a VEGF-neuropilin-1 loop was reported to drive tumour initiation and stemness of cancer cells in the perivascular niche [47] . Likewise, in the brain, a distinct perivascular niche has been described for glioma stem-like cells [48] ; this appears to be involved in the process of malignant transformation of progenitor cells via PTEN dysregulation, which gives rise to medulloblastomas [49] , and has been implicated in radiation resistance of medulloblastoma stem-like cells via phosphoinositide 3-kinase pathway activation [50] . Interestingly, as in the bone marrow, the perivascular niche has a crucial role in normal stem cell function in the brain: neurogenesis depends on tight and reciprocal interactions of blood vessel components, particularly endothelial cells, with neural stem and progenitor cells [51] . Interestingly, perivascular NO gradients play a role both in neurogenesis, driving stem cell proliferation under pathological conditions, including Figure 1 . Blood vessels provide a crucial niche for tumour progression, beyond angiogenesis. Right: the formation of new blood vessels by sprouting and other types of angiogenesis can be dispensable for the growth of tumours. Rather, many tumours co-opt pre-existing blood vessels of the host to obtain access to oxygen and nutrients, but also to the crucial perivascular niche environment. Incorporation of existing blood vessels and the formation of new blood vessels can occur simultaneously in tumours, but can also be regarded as alternative mechanisms of tumour progression when one of these basic mechanisms is blocked. Left: the perivascular niche can provide central cues for tumour initiation, progression, and therapy resistance. EC, endothelial cell; BM, vascular basement membrane.
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hypoxia [51] , and in promoting stemness of perivascular glioma cells via activation of NOTCH signalling [52] . Another candidate is laminin α2, located in the vascular BM, which has been reported to promote the growth of glioblastoma stem-like cells [53] . Finally, a distinct perivascular niche has also been detected for head and neck cancer cells; endothelial-derived epidermal growth factor induced a stem-like phenotype, and indicated an epithelial-mesenchymal transition mechanism of cancer cells [54] . Together, these findings indicate that multiple endothelial cell-derived factors, along with vascular BM-related and other factors, appear to create the specific microenvironment of the perivascular niche in which those stem-like cancer cells that are indispensable for the initiation and maintenance of tumour growth, and for resistance to therapy, are located. Dormancy, the long-term persistence of microscopic tumour disease, is another important aspect of tumour biology related to cancer cell stemness features, and probably the main reason why cancers relapse after long periods of time despite a macroscopic 'full remission' [55] . Using in vivo two-photon microscopy, we found that a small proportion of melanoma, lung and breast cancer cells enter a dormant state after extravasation, and rest as single cells without proliferation or regression over long periods of time, and that this critically depends on a position in the perivascular niche [24] . Ghajar et al confirmed that dormancy in the brain, but also in the lung and bone marrow, was restricted to a position in the perivascular niche. Thrombospondin-1, released from resting endothelium and localized to the vascular BM, mediated cancer cell quiescence [56] . In contrast, transforming growth factor-β1 and periostin were identified as factors released from activated endothelial cells that sparked dormant micrometastatic outgrowth [56] , which is in line with the findings of other groups, who showed that endothelial cell activation was able to drive dormant cells into a proliferative state [57] [58] [59] . The recently observed localization of extravasating/extravasated cancer cells between endothelial cells and the vascular BM, termed 'endothelialization', might explain why cancer cells maintain endothelial and BM factors under such strict control during dormancy and its loss [60] .
Finally, the first evidence is emerging that the perivascular niche might also play a role in immune modulation, potentially immune escape in tumours [61] . For example, perivascular macrophages can drive multiple steps of tumourigenesis and metastasis, recruitment of other leukocyte populations, and therapy response [62] . Likewise, in vivo imaging has helped to shed light on glioma-promoting functions of tissue-resident myeloid cells, i.e. microglia, in the brain perivascular niche [63, 64] .
Conclusions
In summary, the ability to incorporate and to exploit blood vessels of the host, which are pre-existing complex anatomical and physiological structures, emerges as another plausible hallmark of cancer, complementing those that have already been well studied [1] (Figure 1) . Although many open questions remain, including the exact contribution of vascular co-option and perivascular niche dependence in various tumour types and stages of disease progression, it is becoming increasingly clear that therapeutic targeting of vessel exploitation has the potential to add to the armamentarium of cancer therapy. Thus, a rational attack on vessel exploitation might provide much more benefit than overcoming primary or secondary resistance to antiangiogenic therapy: it holds the promise of interfering with multiple central traits of tumour biology. The molecular pathways and cell types that have already been suggested as being relevant for vascular co-option and perivascular niche habitation can provide a cue for future directions of research and drug development.
